---

Mucormycosis: A manifestation in COVID-19 infection

---

Review Article

Author Details : Abhishek Sharma*, Gulnaz Bano, Abdul Malik

Volume : 8, Issue : 3, Year : 2021

Article Page : 189-194

https://doi.org/10.18231/j.ijpp.2021.032

Suggest article by email

Get Permission

---

Abstract

Patients with COVID-19 may develop higher susceptibility to fungal co-infections. Mucormycosis is a rare and often life-threatening disease caused by vascular invasion by hyphae, leading to thrombosis and necrosis. Mucormycosis has been the cause of morbidity and mortality in transplant, ICU and immunodeficient individuals over a long period of time, but in India, a rapid increase in the number of cases seen in unexpected patients with Covid-19, which is a major concern. Covid-19 patients, already immunocompromised with underlying condition, had been exposed to severe Covid-19 infection and been using steroids, were at greater risk of developing mucormycosis. Out of ten cases reported by Sir Ganga Ram Hospital, Delhi India in December2020, five succumbed to mucormycosis. Another unique feature reported in mucor patients was age, most were elderly with ages between 45 to 60 years. The mortality rate is currently estimated at 50% in India. Symptoms such as nasal congestion, swelling of the eye or cheeks and dark brown crusts inside the nose should be reported immediately and anti-fungal treatment should be started.

Keywords: COVID-19 infection, Immunocompromised host, Mucormycosis, Nasal congestion, Thrombosis

How to cite : Sharma A, Bano G, Malik A, Mucormycosis: A manifestation in COVID-19 infection. Indian J Pharm Pharmacol 2021;8(3):189-194

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.